"Acromegaly" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)
| Descriptor ID |
D000172
|
| MeSH Number(s) |
C05.116.132.082 C10.228.140.617.738.250.100 C19.700.355.179
|
| Concept/Terms |
Acromegaly- Acromegaly
- Somatotropin Hypersecretion Syndrome (Acromegaly)
- Hypersecretion Syndrome, Somatotropin (Acromegaly)
- Hypersecretion Syndromes, Somatotropin (Acromegaly)
- Somatotropin Hypersecretion Syndromes (Acromegaly)
- Syndrome, Somatotropin Hypersecretion (Acromegaly)
- Syndromes, Somatotropin Hypersecretion (Acromegaly)
- Inappropriate GH Secretion Syndrome (Acromegaly)
- Inappropriate Growth Hormone Secretion Syndrome (Acromegaly)
|
Below are MeSH descriptors whose meaning is more general than "Acromegaly".
Below are MeSH descriptors whose meaning is more specific than "Acromegaly".
This graph shows the total number of publications written about "Acromegaly" by people in this website by year, and whether "Acromegaly" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Acromegaly" by people in Profiles.
-
A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021 Feb; 24(1):1-13.
-
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. J Clin Endocrinol Metab. 2020 10 01; 105(10).
-
All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Eur J Endocrinol. 2020 Mar; 182(3):285-292.
-
Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. Eur J Endocrinol. 2017 Feb; 176(2):213-220.
-
Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. Drugs. 2016 Sep; 76(13):1235-1243.
-
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol Commun. 2016 06 01; 4(1):56.
-
Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data. Neuroendocrinology. 2015; 102(1-2):8-17.
-
X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer. 2015 Jun; 22(3):353-67.
-
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014 Dec 18; 371(25):2363-74.
-
Development of a modified head and neck quality assurance phantom for use in stereotactic radiosurgery trials. J Appl Clin Med Phys. 2013 Jul 08; 14(4):4313.